Protein therapeutics company Sesen Bio Inc (Nasdaq:SESN) revealed on Monday the election of Dennis Kim, MD, MPH as its chief medical officer.

In this role, Dr Kim will oversee the continued Phase 3 development of Vicinium, Sesen Bio's lead targeted fusion protein, for patients with high-grade non-muscle invasive bladder cancer (NMIBC), as well as preparations for a marketing authorisation submission and pre-commercial activities.

Recently, Dr Kim has held senior and leadership roles at Ipsen, Spectrum, Novartis, Biogen Idec as well as Amgen.

Previously, Dr Kim worked as an epidemic intelligence service officer at the Centers for Disease Control and Prevention, where he played active roles in environmental and infectious disease studies.

Under Nasdaq Stock Market Listing Rule 5635(c)(4), Dr Kim received an option to purchase 425,000 shares of the company's common stock at an exercise price per share equal to the closing price per share of its common stock on The Nasdaq Global Market on 3 December 2018. The stock option will have a ten-year term and will vest over a four-year period, with 25% of the shares underlying the stock option award vesting on the first anniversary of the date of grant and an additional 6.25% of the shares underlying the stock option vesting at the end of each successive three-month period following the one-year anniversary of the date of grant of the stock options.